Antibody-Drug Conjugates

(Image: Getty/BrianAJackson)

AZ’s ADC receives priority review

By Ben Hargreaves

US FDA provides AZ and Daiichi Sankyo’s ADC for the treatment of metastatic breast cancer priority review, with a decision set for Q2 2020.

(Image: Getty/Shidlovski)

Genentech taps Halozyme’s tech in Herceptin Hylecta

By Maggie Lynch

Genentech receives US FDA approval on Herceptin Hylecta, a subcutaneous co-formulation using Halozyme’s recombinant Enhanze technology, for the treatment of HER2-positive metastatic breast cancer.

(Image: Getty/alice-photo)

bioProcess UK Conference

#bioProcessUK dispatches: Driving down the cost of medicine

By Flora Southey

How to best safeguard the biopharmaceutical supply chain? What more can be done to reduce the cost of medicines? This and more was discussed at the Annual bioProcess UK Conference this week in Scotland.